At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 269 enrolled
Drug / intervention
Empagliflozin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control
In Brief
A Phase 4 clinical trial evaluating Empagliflozin and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 269 participants across 48 sites.
Detailed Summary
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionApr 2017
Study CompletionJan 2018
TodayJul 2026
First PostedOct 28, 2015
Enrollment StartOct 28, 2015
Primary CompletionApr 18, 2017
Study CompletionJan 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.7 years ago
Interventions
Empagliflozindrug
Placebodrug
Placebodrug
For blinding purposes